Hal Brown
Family Medicine · Vero Beach, FLNPI 1902804677
Payments from drug & device makers
Across 226 payments — averaging $2112.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SWAN Valley Medical Incorporated$473K
- Amgen$453
- Pfizer$445
- Novo Nordisk$409
- GSK$355
- Novartis$348
- plus $2K from 27 others
What the payments were for
- Consulting fees$413,00087%
- Grants$60,00013%
- Travel & lodging$1960%
- Food & beverage$4,1291%
- Education$140%
- Gifts$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SWAN Valley Medical Incorporated | 12 | $473,196 |
| Amgen | 25 | $453 |
| Pfizer | 25 | $445 |
| Novo Nordisk | 32 | $409 |
| GSK | 14 | $355 |
| Novartis | 17 | $348 |
| Amarin Pharma, Inc. | 18 | $335 |
| Boston Scientific | 3 | $218 |
| AstraZeneca | 11 | $201 |
| Merck | 13 | $196 |
| Daiichi Sankyo Inc. | 7 | $190 |
| Astellas Pharma US Inc | 3 | $150 |
| AbbVie(2 entities) | 7 | $119 |
| Lilly USA, LLC | 7 | $111 |
| Boehringer Ingelheim | 3 | $76 |
| Bausch Health US, LLC | 3 | $68 |
| Sanofi Pasteur Inc. | 3 | $54 |
| Eisai Inc. | 3 | $50 |
| Tosoh Bioscience, Inc. | 1 | $50 |
| Abbott | 2 | $46 |
| Avanir Pharmaceuticals, Inc. | 2 | $45 |
| Johnson & Johnson | 2 | $41 |
| Seqirus USA Inc | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Bioventus LLC | 1 | $25 |
| Roche Diagnostics Corporation | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Vertiflex, Inc. | 1 | $19 |
| Cvrx, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Genentech USA, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$477,389 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $44,109 |
| OzempicSemaglutide | 21 | $24,548 |
| MyrbetriqMirabegron | 17 | $11,806 |
| Atorvastatin Calcium | 231 | $2,964 |
| Rosuvastatin Calcium | 141 | $2,949 |
| Levothyroxine Sodium | 75 | $1,208 |
| Ezetimibe | 31 | $1,183 |
| Valsartan | 35 | $1,170 |
| Bupropion XlBupropion Hcl | 12 | $1,037 |
| Tamsulosin Hcl | 36 | $775 |
| Amlodipine Besylate | 78 | $759 |
| Montelukast Sodium | 25 | $744 |
| Sertraline Hcl | 47 | $700 |
| Escitalopram Oxalate | 29 | $678 |
| Ipratropium Bromide | 14 | $620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $445 | $44,10930 claims |
| Novo NordiskOzempic | $409 | $24,54821 claims |
| Astellas Pharma US IncMyrbetriq | $150 | $11,80617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Vero Beach
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.